BCLS Fund III exits Cidara stake, now reports 0% owned

Cidara Therapeutics investor Bain Capital Life Sciences entity reports no current stake in the company’s common stock.

Rhea-AI Filing Summary

Cidara Therapeutics investor Bain Capital Life Sciences entity reports no current stake in the company’s common stock. An Amendment No. 3 to Schedule 13G/A filed by BCLS Fund III Investments, LP states that, as of December 31, 2025, it beneficially owned 0 shares, representing 0% of Cidara’s outstanding common stock. The filing confirms the reporting person has no sole or shared voting or dispositive power over any Cidara shares and that any securities referenced are not held for the purpose of changing or influencing control of the issuer.

Insights

Equity ownership and governance analyst

BCLS Fund III Investments now reports zero ownership and influence in Cidara.

BCLS Fund III Investments, LP, part of the Bain Capital Life Sciences structure, reports beneficial ownership of 0 Cidara common shares, or 0% of the class as of December 31, 2025. It also reports no sole or shared voting or dispositive power.

This indicates that an institutional holder previously significant enough to require Schedule 13G reporting now falls below reporting thresholds. The filing also certifies that any securities referenced were not acquired or held to change or influence control, aligning with a passive-investor posture.

Future company filings may clarify Cidara’s evolving shareholder base and any new large passive or active holders. For now, this update simply documents that the Bain Capital Life Sciences reporting entity no longer has a reportable ownership position in Cidara.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Schedule 13G/A filing say about BCLS Fund III Investments’ ownership in Cidara Therapeutics (CDTX)?

The filing reports that BCLS Fund III Investments, LP beneficially owned 0 shares of Cidara common stock, representing 0% of the class as of December 31, 2025. It also shows no voting or dispositive power over any Cidara shares.

Who is the reporting person in the Cidara Therapeutics (CDTX) Schedule 13G/A Amendment No. 3?

The reporting person is BCLS Fund III Investments, LP, a Delaware limited partnership associated with the Bain Capital Life Sciences Entities. Bain Capital Life Sciences Investors, LLC is the manager at the top of the ownership chain described in the filing’s Item 2(a).

What percentage of Cidara Therapeutics (CDTX) common stock does BCLS Fund III Investments currently report owning?

BCLS Fund III Investments reports owning 0% of Cidara’s common stock as of December 31, 2025. The Schedule 13G/A lists an aggregate beneficial ownership amount of 0 shares and confirms ownership of five percent or less of the class.

Does BCLS Fund III Investments have voting or dispositive power over Cidara Therapeutics (CDTX) shares?

No. The filing states that BCLS Fund III Investments has 0 shares with sole or shared voting power and 0 shares with sole or shared dispositive power. This means it does not control how any Cidara shares are voted or disposed of.

What does the control and intent certification state in the Cidara Therapeutics (CDTX) Schedule 13G/A?

The certification states the securities referred to were not acquired and are not held to change or influence control of Cidara Therapeutics. It also notes they are not held as part of any transaction with that purpose, aside from activities tied to a nomination under Rule 14a-11.

Who signed the Cidara Therapeutics (CDTX) Schedule 13G/A on behalf of the Bain Capital Life Sciences entities?

The Schedule 13G/A is signed by Andrew Hack, identified as a Partner of Bain Capital Life Sciences Investors, LLC. The signature block includes his name, title, and a signature dated February 17, 2026, certifying the accuracy of the information provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:30 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

CIDARA THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

171757206

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

BCLS Fund III Investments, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CIDARA THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed by BCLS Fund III Investments, LP, a Delaware limited partnership (the "Reporting Person"). Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company ("BCLSI"), is the manager of Bain Capital Life Sciences III General Partner, LLC, a Delaware limited liability company ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P., a Delaware limited partnership ("BCLS Fund III"), which is the managing member of BCLS Fund III Investments GP, LLC, a Delaware limited liability company (together with the Reporting Person, BCLSI, BCLS Fund III GP and BCLS Fund III, the "Bain Capital Life Sciences Entities"), which is the general partner of the Reporting Person. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business address for each of the Bain Capital Life Sciences Entities is 200 Clarendon Street, Boston, Massachusetts 02116.
(c)	Citizenship: Each of the Bain Capital Life Sciences Entities is organized under the laws of the State of Delaware.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 171757206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of the close of business on December 31, 2025, the Reporting Person did not beneficially own any shares of Common Stock.
(b)	Percent of class: See Item 4(a) hereof.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BCLS Fund III Investments, LP

Signature:	/s/ Andrew Hack
Name/Title:	Andrew Hack, Partner of Bain Capital Life Sciences Investors, LLC
Date:	02/17/2026